Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ganirelix.

P S Gillies1, D Faulds, J A Balfour

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand.

Drugs
|March 16, 2000
PubMed
Summary
This summary is machine-generated.

Ganirelix, a gonadotropin-releasing hormone (GnRH) antagonist, effectively prevents LH surges in women undergoing in vitro fertilization. This treatment achieved a 40.3% pregnancy rate, demonstrating its efficacy in fertility treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Levetiracetam.

CNS drugs·2013
Same author

Becaplermin.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Trastuzumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Combination hepatitis a-hepatitis B vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Recombinant Mammalian Cell-Derived Somatropin: A Review of its Pharmacological Properties and Therapeutic Potential in the Management of Wasting Associated with HIV Infection.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Interferon-alpha-n1: a review of its pharmacological properties and therapeutic efficacy in the management of chronic viral hepatitis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Reproductive Endocrinology
  • Pharmacology
  • In Vitro Fertilization

Background:

  • Ganirelix is a synthetic GnRH antagonist.
  • It acts by competitively blocking GnRH receptors in the anterior pituitary.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of Ganirelix in controlled ovarian stimulation for IVF.
  • To assess its ability to prevent premature luteinizing hormone (LH) surges.

Main Methods:

  • A large, multicenter clinical trial.
  • Subcutaneous administration of Ganirelix at a 0.25 mg/day dosage.
  • Monitoring of hormonal profiles and pregnancy rates in women undergoing IVF.

Main Results:

  • Ganirelix effectively inhibited LH surges during controlled ovarian stimulation.

Related Experiment Videos

  • A vital pregnancy rate of 40.3% per embryo transfer was achieved.
  • The drug was generally well-tolerated.

    • Conclusions:

    • Ganirelix is an effective GnRH antagonist for preventing LH surges in IVF.
    • It demonstrates a favorable pregnancy rate and good tolerability profile.
    • Ganirelix is a valuable option for controlled ovarian stimulation protocols.